PATIENTREKRYTERING TILL REGISTRERINGSGRUNDANDE KLINISK FAS III-STUDIE INLEDD FÖR ORALT LAQUINIMOD FÖR BEHANDLING AV RELAPSERANDE REMITTERANDE MULTIPEL SKLEROS

För ytterligare
information, var god
kontakta:
                          Teva Pharmaceutical          972-2-941-1717
Dan Suesskind, Chief      Industries Ltd.
Financial Officer
George Barrett,
Corp. E. V.P. - Global    Teva Pharmaceutical          (215) 591-3030
pharmaceutical Markets    Industries Ltd.
Chief Executive Officer   Teva North America

Liraz Kalif /             Teva Pharmaceutical          972-3-926-7281
Kevin Mannix, Investor    Industries Ltd. Teva North   (215) 591-8912
Relations                 America

Sven Andréasson           Active Biotech               046 19 20 49
Verkställande direktör

Tomas Leanderson Chief    Active Biotech               046 19 20 95
Scientific Officer

Cecilia Hofvander Manager Active Biotech               046 19 11 22
Corporate Communication